OR WAIT 15 SECS
Decentralized and hybrid trials are widely discussed in the pharmaceutical industry and are already being deployed on some clinical studies. There are organizations that are convinced that it is the next big step in making clinical research more patient-centric and this will have a significant impact on the industry challenge of patient recruitment. But what does the patient think? With this objective in mind, a survey was conducted to get the patient view and find out whether bringing the trial to the patient could make a difference. We explored patients’ perceptions and preferences around what makes it easier for them to participate in clinical trials and to determine whether perception was reality.
The industry, sponsors, and sites need to connect and align with patient needs if they really want to improve the patient experience and make the clinical trial truly patient-centric. It is advisable to have the flexibility to customize options from trial to trial, taking into account the study design aspects for example; frequency of visits, complexity, and longevity of study and the patient population criteria such as; age, geography, and disease state.
The patient perspective on clinical trial participation may differ from what is generally expected at an industry level. We need to ask the patients what they want, provide choices for them, and move at their pace rather than move too quickly, increasing the challenges and complexities of participation. Moving too fast could mean slower adoption in the long run.
Gretchen Goller, MSW, global head, Patient Recruitment & Retention Solutions, ICON plc
Kristin Kinlaw, director of communications, PMG Research Inc.
The results of this research were first presented at the Global Site Solutions Summit, held in Hollywood, FL, USA, 11–13 October 2019.
A web based survey was sent via e-mail to patients listed in the ICON owned Global Site Network Databases: 55,220 patients in the PMG Research Database (North America) and 33,000 patients in the MeDiNova Database (EMEA). The survey was also promoted externally via social media and was open for 3 weeks. Number of responses: 4,086.